Clinical Trials Logo

CD30+ Peripheral T-cell Lymphoma clinical trials

View clinical trials related to CD30+ Peripheral T-cell Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03205891 Withdrawn - Clinical trials for Anaplastic Large Cell Lymphoma

Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

Start date: March 2018
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of TAK228 that can be given in combination with brentuximab vedotin in patients with lymphoma. The safety of this combination will also be studied. This is an investigational study. TAK228 is not FDA approved or commercially available. It is currently being used for research purposes only. Brentuximab vedotin is FDA approved and commercially available for the treatment of different types of lymphoma. The study doctor can explain how the study drugs are designed to work. Up to 18 participants will be enrolled in this study. All will take part at MD Anderson.